Medical Access and Reimbursement in Netherlands

Psilocybin should be split into two categories in the Netherlands. Fresh and dried psilocybin mushrooms are prohibited, while truffles can be sold legally in the non-medical retail market. That retail legality does not create an authorised treatment, compassionate-use or reimbursement pathway. # #

In healthcare, psilocybin remains clinical-research only. Dutch government guidance states that most therapeutic psychedelics are not registered medicines and cannot be prescribed, and UMCG's PsyPal programme is a regulated research study rather than routine care. # # #

MDMA-assisted therapy is not an authorised Dutch treatment. The government's 2025 response kept MDMA inside the ordinary medicines-development route and stated that MDMA can currently be administered only in clinical research. ARQ likewise describes MDMA-supported therapy as research-phase only and says its METC-approved PTSD study is not yet open for enrolment. # #

Esketamine nasal spray is the clearest national access route. Spravato is authorised in the EU for treatment-resistant major depressive disorder, and Zorginstituut records that esketamine nasal spray has been reimbursed from the Dutch basic insurance package since 1 September 2021 under restricted conditions. # #

Oral esketamine is separate. Zorginstituut describes the UMCG-led oral esketamine project as promising-care evidence development and says oral esketamine does not yet meet the state-of-science-and-practice test for reimbursement from the basic package, with a formal position expected in June 2026. # #

Ketamine and esketamine are used in some Dutch specialist psychiatric settings, but this is centre-specific and should not be described as broad insured psychedelic therapy. UMCG says hard-to-treat depression patients can sometimes receive off-label esketamine and that it is running ketamine/esketamine studies. #

The Dutch government distinguishes off-label esketamine or ketamine from non-authorised classical psychedelics. Off-label use must satisfy professional standards and protocols, while most therapeutic psychedelics cannot simply be prescribed because they are not registered medicines. # #

DMT has a visible Dutch early-phase research footprint through CHDR in Leiden, which reports completed intravenous DMT pharmacology work in healthy volunteers. No Dutch market authorisation, reimbursement route or routine medical access pathway for DMT-assisted therapy was identified in the sources reviewed. # #

The Netherlands has academic links to 5-MeO-DMT research, including a Maastricht University publication record for a phase 1/2 study in treatment-resistant depression. No Dutch market authorisation or reimbursement route for 5-MeO-DMT was identified, and the exact legal impact of the July 2025 designer-drug reform should be checked before publishing a detailed scheduling table. # #

No Dutch market authorisation, reimbursement route or routine medical access pathway for ibogaine was identified in the reviewed public sources. Any future claim about ibogaine scheduling or clinic availability should be verified directly against current Dutch law and regulator guidance. # #

Ayahuasca is not a recognised Dutch therapeutic or ceremonial medical access route. The Dutch Supreme Court confirmed that religious ayahuasca ceremonies are prohibited, and public-health guidance likewise treats ayahuasca/DMT as illegal in this context. # #

No Dutch market authorisation, reimbursement route or routine medical access pathway for mescaline-assisted therapy was identified. The relevant healthcare rule remains that non-registered therapeutic psychedelics cannot be prescribed and can be administered only within authorised research. # #

No Dutch authorised or reimbursed medical pathway for 2C-X therapy was identified. The July 2025 List IA reform is relevant because it added broad groups of new psychoactive substances, including phenethylamines, to the Opium Act framework, but that reform is a control measure rather than a clinical-access pathway. #